BLTE BELITE BIO, INC: institutional ownership and insider trading
82 funds reported holding $1.44B of BELITE BIO, INC in their latest 13F filings; in Q2 2026 funds net bought $55.0M, with 21 new positions and 16 funds selling out; over the last 12 months insiders bought $0 and sold $40.6M on the open market.
Famous investors holding BLTE
- Lee Ainslie (Maverick Capital): $61.0M, 0.5% of the portfolio
- Stanley Druckenmiller (Duquesne Family Office): $16.3M, 0.3% of the portfolio
- Izzy Englander (Millennium Management): $76.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $8.59M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $28.7M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $5.87M, 0.0% of the portfolio
Largest institutional holders of BLTE
- Darwin Global Management, Ltd. — $457M
- Paradigm Biocapital Advisors LP — $190M
- RTW INVESTMENTS, LP — $110M
- MILLENNIUM MANAGEMENT LLC — $76.2M
- MAVERICK CAPITAL LTD — $61.0M
- EVENTIDE ASSET MANAGEMENT, LLC — $60.2M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $55.0M
- Holocene Advisors, LP — $38.7M
- Logos Global Management LP — $38.5M
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $36.2M
Recent BLTE insider trades
- Oct 1, 2026: Scholl Hendrik Peter sold 500 shares ($82.7K)
- Sep 8, 2026: Chuang Hao-Yuan sold 67,395 shares ($12.8M)
- Sep 8, 2026: Lin Yu-Hsin sold 100,435 shares ($19.1M)
- Aug 12, 2026: Lin Yu-Hsin sold 365 shares ($65.8K)
5%+ owners
- Lin Bioscience International Ltd.: 53.7% (Schedule 13G, filed Jan 21, 2025)
- Darwin Global Management, Ltd.: 8.1% (Schedule 13G/A, filed Feb 17, 2026)